The role of COX-2 as an oncogene and its suppression of anti-tumour immunity has been extensively studied in mammalian models, and EP4 inhibitors have been suggested in cancer therapeutic and immunotherapy approaches (53, 54). This evidence concerns the gene PTGS2 and neoplasm.